LRT Capital Management LLC Purchases Shares of 1,188 IDEXX Laboratories, Inc. $IDXX

LRT Capital Management LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,188 shares of the company’s stock, valued at approximately $759,000.

Other large investors have also made changes to their positions in the company. Lido Advisors LLC boosted its holdings in IDEXX Laboratories by 105.8% in the third quarter. Lido Advisors LLC now owns 4,066 shares of the company’s stock valued at $2,598,000 after acquiring an additional 2,090 shares during the last quarter. JPL Wealth Management LLC purchased a new stake in IDEXX Laboratories during the third quarter valued at about $68,000. Gotham Asset Management LLC increased its stake in IDEXX Laboratories by 40.4% during the third quarter. Gotham Asset Management LLC now owns 48,643 shares of the company’s stock worth $31,078,000 after acquiring an additional 13,986 shares during the last quarter. Fred Alger Management LLC raised its holdings in shares of IDEXX Laboratories by 60.8% in the 3rd quarter. Fred Alger Management LLC now owns 27,075 shares of the company’s stock worth $17,298,000 after purchasing an additional 10,236 shares during the period. Finally, Focus Partners Wealth raised its holdings in shares of IDEXX Laboratories by 1.4% in the 3rd quarter. Focus Partners Wealth now owns 51,918 shares of the company’s stock worth $33,170,000 after purchasing an additional 724 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on IDXX shares. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. UBS Group reduced their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

Insider Activity

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This represents a 21.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Nimrata Hunt sold 2,693 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total value of $1,781,527.22. Following the sale, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. The trade was a 11.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock worth $29,862,109 over the last ninety days. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 2.2%

NASDAQ IDXX opened at $586.37 on Tuesday. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The business has a 50 day moving average price of $656.25 and a two-hundred day moving average price of $666.45. The stock has a market cap of $46.69 billion, a PE ratio of 44.86, a P/E/G ratio of 3.48 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business earned $2.53 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.